Clinical Trials Logo

Amyloidosis; Systemic clinical trials

View clinical trials related to Amyloidosis; Systemic.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06192979 Recruiting - AL Amyloidosis Clinical Trials

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Start date: January 5, 2024
Phase: N/A
Study type: Interventional

Achievement of complete hematologic response (CHR) is vital for systemic AL amyloidosis. Currently, the CHR rate of daratumumab, bortezomib, and dexamethasone (DBD) is close to 60%. Considering that Bcl-2 inhibitor is effective for AL amyloidosis with t(11; 14) and the median hematologic onset time of DBD is 7 days. We design a a prospective study on AL amyloidosis with t(11; 14). All patients receive DBD at the beginning. Patient will receive DBD for at least 6 cycles if achieve rapid hematologic response at day 7, while other patients will receive daratumumab, venetoclax and dexamethasone.

NCT ID: NCT05951049 Recruiting - Clinical trials for Amyloidosis; Systemic

A Study of AT-02 in Subjects With Systemic Amyloidosis.

Start date: September 21, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02. AT-02 is an investigational medicinal product being developed to treat systemic amyloidosis.

NCT ID: NCT05521022 Recruiting - Clinical trials for Amyloidosis; Systemic

Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

AT02-001
Start date: September 1, 2022
Phase: Phase 1
Study type: Interventional

This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.